Efek samping minor penggunaan obat ini meliputi rasa lelah, ruam, gangguan hati, nyeri otot, dan batuk.[3] Efek samping yang mayor penggunaan obat ini seperti: gangguan pada paru-paru, gangguan pada usus, gangguan fungsi hati, gangguan ginjal, masalah kulit, atau endokrin yang berhubungan dengan sistem kekebalan tubuh.[3] Nivolumab tidak direkomendasikan untuk ibu hamil dan ibu menyusui.[3] Nivolumab merupkan antibodi monoklonalIgG4 manusia yang bekerja untuk memblokir PD-1.[3] Nivolumab merupakan imunoterapi, mekanisme kerja obat ini menghambat titik kontrol, memblokir sinyal yang menghambat aktivasi sel T untuk menyerang sel kanker.[3][2]
↑World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
Pranala luar
"Nivolumab". NCI Drug Dictionary. National Cancer Institute.
"Nivolumab". National Cancer Institute. 7 January 2015.
Nomor uji klinis NCT01721746 for "A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)" di ClinicalTrials.gov
Nomor uji klinis NCT01721772 for "Study of Nivolumab (BMS-936558) Compared With Dacarbazine in Untreated, Unresectable, or Metastatic Melanoma (CheckMate 066)" di ClinicalTrials.gov
Nomor uji klinis NCT01844505 for "Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067)" di ClinicalTrials.gov
Nomor uji klinis NCT02388906 for "Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma (CheckMate 238)" di ClinicalTrials.gov
Nomor uji klinis NCT02477826 for "An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC) (CheckMate 227)" di ClinicalTrials.gov
Nomor uji klinis NCT03215706 for "A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy Alone in First Line NSCLC (CheckMate 9LA)" di ClinicalTrials.gov
Nomor uji klinis NCT01642004 for "Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC) (CheckMate 017)" di ClinicalTrials.gov
Nomor uji klinis NCT01673867 for "Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Metastatic Non-squamous NSCLC (CheckMate057)" di ClinicalTrials.gov
Nomor uji klinis NCT02899299 for "Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients (CheckMate743)" di ClinicalTrials.gov
Nomor uji klinis NCT02231749 for "Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)" di ClinicalTrials.gov
Nomor uji klinis NCT03141177 for "A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 9ER)" di ClinicalTrials.gov
Nomor uji klinis NCT01668784 for "Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CheckMate 025)" di ClinicalTrials.gov
Nomor uji klinis NCT02181738 for "Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational) (CheckMate 205)" di ClinicalTrials.gov
Nomor uji klinis NCT01592370 for "An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma" di ClinicalTrials.gov
Nomor uji klinis NCT02105636 for "Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141)" di ClinicalTrials.gov
Nomor uji klinis NCT02387996 for "A Study of Nivolumab in Participants With Metastatic or Unresectable Bladder Cancer" di ClinicalTrials.gov
Nomor uji klinis NCT02060188 for "An Investigational Immuno-therapy Study of Nivolumab, and Nivolumab in Combination With Other Anti-cancer Drugs, in Colon Cancer That Has Come Back or Has Spread (CheckMate142)" di ClinicalTrials.gov
Nomor uji klinis NCT01658878 for "An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advanced Liver Cancer (CheckMate040)" di ClinicalTrials.gov
Nomor uji klinis NCT02743494 for "An Investigational Immuno-therapy Study of Nivolumab or Placebo in Participants With Resected Esophageal or Gastroesophageal Junction Cancer (CheckMate 577)" di ClinicalTrials.gov
Nomor uji klinis NCT02569242 for "Study of Nivolumab in Unresectable Advanced or Recurrent Esophageal Cancer" di ClinicalTrials.gov
Nomor uji klinis NCT02872116 for "Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer (CheckMate649)" di ClinicalTrials.gov
Nomor uji klinis NCT02632409 for "An Investigational Immuno-therapy Study of Nivolumab, Compared to Placebo, in Patients With Bladder or Upper Urinary Tract Cancer, Following Surgery to Remove the Cancer (CheckMate 274)" di ClinicalTrials.gov
Artikel bertopik farmakologi ini adalah sebuah rintisan. Anda dapat membantu Wikipedia dengan mengembangkannya.
